Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Buy
54
XFOR Quote, Financials, Valuation and Earnings
Last price:
$4.12
Seasonality move
:
-4.47%
Day range:
$4.01 - $4.27
52-week range:
$1.35 - $26.83
Dividend yield:
0%
P/E ratio:
0.70x
P/S ratio:
1.95x
P/B ratio:
5.85x
Volume:
853.4K
Avg. volume:
780.5K
1-year change:
-76.2%
Market cap:
$360.2M
Revenue:
$2.6M
EPS (TTM):
-$10.01
Analysts' Opinion
-
Consensus RatingX4 Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.00, X4 Pharmaceuticals, Inc. has an estimated upside of 94.18% from its current price of $4.12.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $4.12.
Fair Value
-
According to the consensus of 3 analysts, X4 Pharmaceuticals, Inc. has 94.18% upside to fair value with a price target of $8.00 per share.
XFOR vs. S&P 500
-
Over the past 5 trading days, X4 Pharmaceuticals, Inc. has overperformed the S&P 500 by 8.88% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
X4 Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
X4 Pharmaceuticals, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter X4 Pharmaceuticals, Inc. reported revenues of $1.8M.
Earnings Growth
-
X4 Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter X4 Pharmaceuticals, Inc. reported earnings per share of -$0.69.
Enterprise value:
315.2M
EV / Invested capital:
2.27x
Price / LTM sales:
1.95x
EV / EBIT:
-0.03x
EV / Revenue:
9.28x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-2.97x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
-0.02x
Gross Profit (TTM):
$27.7M
Return On Assets:
-65.73%
Net Income Margin (TTM):
-279.86%
Return On Equity:
-279.19%
Return On Invested Capital:
-84.9%
Operating Margin:
-1558.58%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $1.1M | $34M | $560K | $1.8M | |
| Gross Profit | -$2M | $230K | $27.7M | $253K | $1.4M | |
| Operating Income | -$107.9M | -$130.9M | -$98.9M | -$34.5M | -$27.5M | |
| EBITDA | -$105.9M | -$130.3M | -$97.5M | -$34.2M | -$27.3M | |
| Diluted EPS | -$0.80 | -$0.09 | -$10.01 | -$0.18 | -$0.69 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $80.7M | $85.7M | $147.9M | $143M | $132.8M | |
| Total Assets | $120.5M | $113.4M | $173.3M | $178.2M | $163.6M | |
| Current Liabilities | $13.2M | $28.7M | $25.4M | $29.3M | $23.5M | |
| Total Liabilities | $51.8M | $51.6M | $105.7M | $118.5M | $101.9M | |
| Total Equity | $68.7M | $61.8M | $67.6M | $59.6M | $61.6M | |
| Total Debt | $39.8M | $37.2M | $57.2M | $77M | $76.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$87.9M | -$125.7M | -$103.1M | -$34M | -$27.8M | |
| Cash From Investing | -$10.1M | $70.8M | -$17.3M | -$15.9M | -$28.7M | |
| Cash From Financing | $149.1M | $20.3M | $92.7M | -- | $86.9M | |
| Free Cash Flow | -$87.9M | -$126M | -$106.1M | -$34.1M | -$27.8M | |
XFOR
Sector
Market Cap
$360.2M
$28.1M
Price % of 52-Week High
15.36%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-107.55%
-1.49%
1-Year Price Total Return
-76.2%
-17.13%
Beta (5-Year)
0.421
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.80
200-day SMA
Buy
Level
$3.81
Bollinger Bands (100)
Buy
Level
2.78 - 3.98
Chaikin Money Flow
Sell
Level
-1.9M
20-day SMA
Buy
Level
$3.70
Relative Strength Index (RSI14)
Buy
Level
60.13
ADX Line
Buy
Level
20.86
Williams %R
Sell
Level
-14.7059
50-day SMA
Buy
Level
$3.62
MACD (12, 26)
Buy
Level
0.96
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Sell
Level
-3.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.8404)
Sell
CA Score
(Annual)
Level (-5.9504)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (4.8213)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The firm is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, XFOR has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XFOR average analyst price target in the past 3 months is $8.00.
-
Where Will X4 Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that X4 Pharmaceuticals, Inc. share price will rise to $8.00 per share over the next 12 months.
-
What Do Analysts Say About X4 Pharmaceuticals, Inc.?
Analysts are divided on their view about X4 Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that X4 Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is X4 Pharmaceuticals, Inc.'s Price Target?
The price target for X4 Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $8.00 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is XFOR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for X4 Pharmaceuticals, Inc. is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of XFOR?
You can purchase shares of X4 Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase X4 Pharmaceuticals, Inc. shares.
-
What Is The X4 Pharmaceuticals, Inc. Share Price Today?
X4 Pharmaceuticals, Inc. was last trading at $4.12 per share. This represents the most recent stock quote for X4 Pharmaceuticals, Inc.. Yesterday, X4 Pharmaceuticals, Inc. closed at $4.12 per share.
-
How To Buy X4 Pharmaceuticals, Inc. Stock Online?
In order to purchase X4 Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get XFOR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
XFOR
Sector
P/E ratio
0.70x
23.89x
PEG ratio
0.00x
-0.01x
P/B ratio
5.85x
1.81x
Price / LTM sales
1.95x
1.59x
Growth Metrics
XFOR
Sector
Revenue growth
215.18%
4.62%
Earnings growth
-277.12%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.84
-$0.21
Profitability
XFOR
Sector
Profitability FY 2024
$1.5M
$3.6M
Return on invested capital
-84.9%
-31.84%
Return on assets
-65.73%
-27.96%
Return on equity
-279.19%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
24
Estimated Next Earnings Date
Feb
4
Balance Sheet
XFOR
Sector
Total cash
$122.4M
$26.4M
Short term investments
$46.4M
$25.7M
Total assets
$146.4M
$76.9M
Long term debt
$76.2M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 3.24% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 1.39% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
